Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dolby Laboratories (DLB) EBITDA (2016 - 2025)

Dolby Laboratories' EBITDA history spans 17 years, with the latest figure at $62.2 million for Q4 2025.

  • For Q4 2025, EBITDA fell 22.18% year-over-year to $62.2 million; the TTM value through Dec 2025 reached $247.2 million, down 9.1%, while the annual FY2025 figure was $265.0 million, 2.57% up from the prior year.
  • EBITDA reached $62.2 million in Q4 2025 per DLB's latest filing, up from $29.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $109.2 million in Q1 2023 to a low of -$3.5 million in Q3 2023.
  • Average EBITDA over 5 years is $59.4 million, with a median of $51.9 million recorded in 2021.
  • Peak YoY movement for EBITDA: tumbled 112.89% in 2023, then soared 1426.67% in 2024.
  • A 5-year view of EBITDA shows it stood at $90.6 million in 2021, then rose by 3.87% to $94.1 million in 2022, then fell by 29.62% to $66.2 million in 2023, then grew by 20.63% to $79.9 million in 2024, then dropped by 22.18% to $62.2 million in 2025.
  • Per Business Quant, the three most recent readings for DLB's EBITDA are $62.2 million (Q4 2025), $29.7 million (Q3 2025), and $47.6 million (Q2 2025).